Fort Washington Investment Advisors Inc. OH Grows Position in Progyny, Inc. $PGNY

Fort Washington Investment Advisors Inc. OH grew its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 10.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,834,104 shares of the company’s stock after acquiring an additional 177,546 shares during the quarter. Fort Washington Investment Advisors Inc. OH owned about 2.13% of Progyny worth $47,100,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Federated Hermes Inc. raised its stake in Progyny by 147.3% in the third quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock valued at $30,000 after purchasing an additional 819 shares in the last quarter. Versant Capital Management Inc grew its stake in Progyny by 61.8% in the 3rd quarter. Versant Capital Management Inc now owns 2,340 shares of the company’s stock worth $50,000 after buying an additional 894 shares in the last quarter. Covestor Ltd grew its stake in Progyny by 164.9% in the 3rd quarter. Covestor Ltd now owns 2,609 shares of the company’s stock worth $56,000 after buying an additional 1,624 shares in the last quarter. Quarry LP increased its holdings in shares of Progyny by 2,004.1% in the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after buying an additional 3,427 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in shares of Progyny in the 2nd quarter worth $77,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Stock Performance

Shares of PGNY opened at $17.79 on Friday. Progyny, Inc. has a fifty-two week low of $16.75 and a fifty-two week high of $28.75. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of 27.37, a PEG ratio of 1.02 and a beta of 1.01. The firm has a 50 day moving average price of $20.75 and a 200-day moving average price of $22.41.

Progyny (NASDAQ:PGNY) last released its earnings results on Thursday, February 26th. The company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.38 by $0.10. The company had revenue of $318.40 million for the quarter, compared to analyst estimates of $314.26 million. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.42 EPS. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, equities research analysts predict that Progyny, Inc. will post 0.6 earnings per share for the current year.

Insider Activity

In other news, EVP Allison Swartz sold 4,657 shares of Progyny stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total value of $81,031.80. Following the transaction, the executive vice president owned 89,879 shares in the company, valued at approximately $1,563,894.60. The trade was a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 7,455 shares of company stock worth $129,515 over the last quarter. 9.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Citizens Jmp raised shares of Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price objective for the company in a report on Tuesday, January 20th. JPMorgan Chase & Co. set a $35.00 target price on Progyny in a research note on Wednesday, January 21st. Barclays lowered their price target on Progyny from $29.00 to $23.00 and set an “overweight” rating on the stock in a research report on Friday, March 20th. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. Finally, KeyCorp reduced their price objective on Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Nine investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Progyny has an average rating of “Moderate Buy” and an average price target of $27.91.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.